The "Autism - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Autism - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 4, 1, 21, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.
Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Reasons to Buy
Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).
Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of leading companies.
Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Topics Covered:
Autism - Overview
Autism - Therapeutics Development
Autism - Therapeutics Assessment
Autism - Companies Involved in Therapeutics Development
Autism - Drug Profiles
Autism - Dormant Projects
Autism - Discontinued Products
Autism - Product Development Milestones
4D Pharma Plc
AgoneX Biopharmaceuticals Inc
Benuvia Therapeutics Inc
Blackthorn Therapeutics Inc
BrainStorm Cell Therapeutics Inc
Cennerv Pharma (S) Pte Ltd
Cox Biosciences LLC
Epigen Biosciences Inc
F. Hoffmann-La Roche Ltd
Finch Therapeutics Group
GW Pharmaceuticals Plc
Intra-Cellular Therapies Inc
Johnson & Johnson
MD Healthcare Inc
OptiNose US Inc
Oryzon Genomics SA
Panorama Research Inc
Park Active Molecules
Reviva Pharmaceuticals Inc
Rugen Therapeutics R&D (Shanghai) Co Ltd
Scioto Biosciences Inc
Sengenics International Pte Ltd
Stem Cell Medicine Ltd
Sumitomo Dainippon Pharma Co Ltd
Therapix Biosciences Ltd
Zelira Therapeutics Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/rcmr1g
View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005627/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900